Status:
COMPLETED
Therapeutic Role of Transcranial DCS in Alzheimer
Lead Sponsor:
Assiut University
Conditions:
Alzheimer Disease
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the oxidative stress and brain damage biomarkers induced by tDCS in patients with AD and to assess the long term neurophysiological and behavioral effects after re...
Detailed Description
The aim of this study is to evaluate the oxidative stress and brain damage biomarkers induced by tDCS in patients with AD and to assess the long term neurophysiological and behavioral effects after re...
Eligibility Criteria
Inclusion
- All subject were diagnosed with Probable AD according to NINCDS/ADRDA Criteria for Alzheimer's Disease.
- Onset age \> 60.
- All 4 grandparents are of Ashkenazi Jewish origin as declared by the subject.
- Subject or subject's legal representative has signed the informed consent form.
Exclusion
- All subjects who were diagnosed with Possible AD according to NINCDS/ADRDA Criteria for Alzheimer's Disease.
- Subjects who were diagnosed with dementia due to other diseases, or with AD and contribution of other disorders (Mixed dementia):
- Brain CT/MRI suggesting alternative diagnoses, such as intracranial space occupying lesions, vascular lesion of the brain, white matter lesion, or hydrocephalus.
- Subjects who had known carrier of a blood transmitted infectious disease or suffers from conditions in which phlebotomy is contra-indicated.
Key Trial Info
Start Date :
August 12 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03313518
Start Date
August 12 2016
End Date
October 10 2017
Last Update
October 18 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.